A Rollover Study to Provide Continued Treatment With Eltrombopag

Autores
Categoría Estudio primario
Registro de estudiosclinicaltrials.gov
Año 2013

Este artículo no está incluido en ninguna revisión sistemática

Cargando información sobre las referencias
The objective of this study was to provide continued treatment with eltrombopag for subjects who were participating in a Novartis-sponsored investigational study with eltrombopag (parent studies 114968/ASPIRE (NCT01440374), PMA112509 (NCT00903422), and TRA105325/EXTEND (NCT00351468), receiving clinical benefit without unacceptable toxicity and to collect long-term safety data.
Epistemonikos ID: 64e888316692fe04fe9ee7d063e801befda089aa
First added on: May 11, 2024